This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Surbone, A. Articles by Cowan, K. H. Search for Related Content PubMed PubMed Citation Articles by Surbone, A. Articles by Cowan, K. H.

Phase I and Pharmacokinetic Study of Arabinofuranosyl-5-azacytosine (Fazarabine, NSC 281272)

Medicine Branch [A. S., N. B-B., R. V. T., R. F., K. H. C.] and Laboratory of Medicinal Chemistry [H. F., J. A. K.], National Cancer Institute, Bethesda, Maryland 20892

A Phase I clinical trial of 1-ß-D-arabinofuranosyl-5-azacytosine (ara-AC or fazarabine) given as a 72-h continuous infusion on a 21-day cycle was conducted in 27 adult patients with refractory cancer. The major toxicity was reversible granulocytopenia and thrombocytopenia. Dose-limiting toxicity was observed at a dose rate of 1.96 mg/m²/h in which Grade IV leukopenia (WBC <1,000/mm³) occurred in 4 of 11 patients and Grade IV thrombocytopenia (platelets <25,000/mm³) occurred in 3 of 11 patients. Plasma steady-state levels ranged from 0.13 to 0.6 µM for doses of 1.25 to 5.94 mg/m²/h. Mean total body clearance was 647 ml/min/m². Minor clinical responses were seen in one patient with testicular cancer, one patient with colon cancer, one patient with breast cancer, and one patient with acute nonlymphocytic leukemia. Another patient with adenocarcinoma of unknown primary had stable disease during 13 cycles of therapy. Based on the results of this study, the recommended dose for Phase II studies of 1-ß-D-arabinofuranosyl-5-azacytosine administered as a 72-h continuous infusion is 2.0 mg/m²/h (48 mg/m²/day).

¹ To whom requests for reprints should be addressed, at Medicine Branch, National Cancer Institute, NIH, Bldg. 10, Rm. 12N226, Bethesda, MD 20892.

Received 4/17/89. Revised 10/20/89. Accepted 11/ 9/89.

This article has been cited by other articles:

				J. Goffin and E. Eisenhauer DNA methyltransferase inhibitors--state of the art Ann. Onc., November 1, 2002; 13(11): 1699 - 1716. [Abstract] [Full Text] [PDF]